Syndicated Report

Pulmonary Arterial Hypertension Causes and Treatments

February 12, 2019

Research Objectives:

  • Understand the current pulmonary arterial hypertension (PAH) patient and treatment landscape
  • Explore physician understanding of new treatments in development for PAH and their expectations

Methodology:
Method: 8-minute MicroSurvey via InCrowd
Crowds: US Cardiologists, US Pulmonologists
Sample Size: n=50
Fielding Period: January 30, 2019
Screening Criteria: Qualified respondents are US-based Cardiologists and Pulmonologists who…
• Have at least five PAH patients under their care
• Are aware of products in development for the treatment of PAH

Two key findings:

  • Most physicians feel that increased patient survival, improved health-related quality of life, and improved functional class are the most important clinical trial endpoints for new PAH treatments.
  • Almost half of physicians agree that the ideal mechanism of action (MOA) for new PAH drugs in development should be selective pulmonary vasodilation.

Download the full report now!

    InCrowd uses the information you provide to us to contact you about our relevant insights, products, and services. You may opt out of communications at any time via the unsubscribe link at the bottom of any email or by sending an email withdrawing your consent to Send Email. For more information, please review our Privacy Policy.
  • This field is for validation purposes and should be left unchanged.